Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California.
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham & Women's Hospital, Boston, Massachusetts.
Clin Gastroenterol Hepatol. 2024 Jul;22(7):1444-1452.e4. doi: 10.1016/j.cgh.2024.02.006. Epub 2024 Feb 23.
BACKGROUND & AIMS: Guidelines recommend hospitalization for severe immune checkpoint inhibitor (ICI) hepatitis. We compared patient outcomes in the inpatient versus outpatient settings.
We conducted a multicenter, retrospective cohort study of 294 ICI-treated patients who developed grade 3-4 ICI hepatitis. The primary outcome was time to alanine aminotransferase (ALT) normalization (≤40); secondary outcomes included time to ALT ≤100 U/L and time to death. To account for confounding by indication, inverse probability of treatment weighting was applied to perform Cox regression. A sensitivity analysis was performed excluding patients with grade 4 hepatitis.
One hundred and sixty-six patients (56.5%) were hospitalized for a median of 6 (interquartile range, 3-11) days. On inverse probability of treatment weighting Cox regression, hospitalization was not associated with time to ALT normalization (hazard ratio [HR], 1.11; 95% confidence interval [CI], 0.86-1.43; P = .436) or time to ALT ≤100 U/L (HR, 1.11; 95% CI, 0.86-1.43; P = .420). In the sensitivity analysis limited to patients with grade 3 hepatitis, hospitalization was also not associated with time to ALT normalization (HR, 1.11; 95% CI, 0.83-1.50; P = .474) or time to ALT ≤100 U/L (HR, 1.19; 95% CI, 0.90-1.58; P = .225). In a subgroup analysis of 152 patients with melanoma, hospitalization was not associated with reduced risk of all-cause death (HR, 0.93; 95% CI, 0.53-1.64; P = .798). Notably, despite their Common Terminology Criteria for Adverse Events classification of high-grade hepatitis, 94% of patients had "mild" liver injury based on International Drug-Induced Liver Injury Criteria.
Hospitalization of patients with high-grade ICI hepatitis was not associated with faster hepatitis resolution and did not affect mortality. Routine hospitalization may not be necessary in all patients with high-grade ICI hepatitis and Common Terminology Criteria for Adverse Events criteria may overestimate severity of liver injury.
指南建议因严重免疫检查点抑制剂(ICI)肝炎住院治疗。我们比较了门诊和住院环境中患者的结局。
我们对 294 例接受 ICI 治疗后发生 3-4 级 ICI 肝炎的患者进行了多中心、回顾性队列研究。主要结局是丙氨酸氨基转移酶(ALT)正常化(≤40)的时间;次要结局包括 ALT≤100 U/L 的时间和死亡时间。为了考虑适应证偏倚,采用逆概率治疗加权法进行 Cox 回归分析。进行了排除 4 级肝炎患者的敏感性分析。
166 例(56.5%)患者因中位住院时间 6(四分位距,3-11)天而住院。在逆概率治疗加权 Cox 回归中,住院与 ALT 正常化时间(风险比[HR],1.11;95%置信区间[CI],0.86-1.43;P=0.436)或 ALT≤100 U/L 的时间(HR,1.11;95%CI,0.86-1.43;P=0.420)无关。在仅包括 3 级肝炎患者的敏感性分析中,住院与 ALT 正常化时间(HR,1.11;95%CI,0.83-1.50;P=0.474)或 ALT≤100 U/L 的时间(HR,1.19;95%CI,0.90-1.58;P=0.225)也无关。在 152 例黑色素瘤患者的亚组分析中,住院与全因死亡风险降低无关(HR,0.93;95%CI,0.53-1.64;P=0.798)。值得注意的是,尽管根据通用不良事件术语标准对他们进行了高等级肝炎分类,但根据国际药物诱导肝损伤标准,94%的患者存在“轻度”肝损伤。
高等级 ICI 肝炎患者的住院治疗与更快的肝炎缓解无关,也不会影响死亡率。并非所有高等级 ICI 肝炎和通用不良事件标准患者都需要常规住院治疗,该标准可能高估了肝损伤的严重程度。